PolyTherics Merges with Antitope
UK-based PolyTherics Limited has merged with Antitope Limited, a provider of antibody engineering and immunogenicity screening services. PolyTherics is issuing new shares up to an aggregate value of 13.5 million pounds ($20.8 million) to fund the merger with Antitope and to provide working capital for the enlarged group. Imperial Innovations led the investment and brought in new investor Invesco Perpetual with further funds provided by Mercia Fund Management and Advantage Enterprise & Innovation Fund.
29 July 2013•4 mins read
